AML1 mutation and its coexistence with different transcription factor gene families in de novo acute myeloid leukemia (AML): redundancy or synergism
- PMID: 17550866
- DOI: 10.3324/haematol.10914
AML1 mutation and its coexistence with different transcription factor gene families in de novo acute myeloid leukemia (AML): redundancy or synergism
Abstract
AML1 mutations were identified in 6.3% of AML patients with chromosomal translocations involving CBF, PML-RARalpha, HOX, or ETS transcription factor (TF) gene families. Rare chromosomal abnormalities, t(16;21) and t(7;11), were also found. This study represents the first series to demonstrate the coexistence of known and novel AML1 mutations with different TF gene mutations. Although the occurrence of two TF gene mutations may appear unnecessary, the possible synergistic mechanism between different TF gene families cannot be excluded and needs to be further explored.
Similar articles
-
The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.Haematologica. 1997 May-Jun;82(3):364-70. Haematologica. 1997. PMID: 9234595 Review.
-
Haematological & molecular profile of acute myelogenous leukaemia in India.Indian J Med Res. 2009 Mar;129(3):256-61. Indian J Med Res. 2009. PMID: 19491417
-
Transcription of the AML1/ETO chimera is guided by the P2 promoter of the AML1 gene in the Kasumi-1 cell line.Gene. 2012 Dec 1;510(2):142-6. doi: 10.1016/j.gene.2012.09.028. Epub 2012 Sep 17. Gene. 2012. PMID: 22995345
-
AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403. doi: 10.1073/pnas.171321298. Proc Natl Acad Sci U S A. 2001. PMID: 11526243 Free PMC article.
-
New mechanisms of AML1 gene alteration in hematological malignancies.Leukemia. 2003 Jan;17(1):9-16. doi: 10.1038/sj.leu.2402766. Leukemia. 2003. PMID: 12529654 Review.
Cited by
-
Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9.Int J Hematol. 2008 Dec;88(5):571-574. doi: 10.1007/s12185-008-0198-9. Epub 2008 Nov 13. Int J Hematol. 2008. PMID: 19005624
-
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5. J Hematol Oncol. 2012. PMID: 22397365 Free PMC article.
-
CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t(16;21)(p11;q22).Int J Hematol. 2010 Sep;92(2):306-13. doi: 10.1007/s12185-010-0650-5. Epub 2010 Aug 10. Int J Hematol. 2010. PMID: 20694842
-
Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.Nat Med. 2012 Feb 26;18(3):436-40. doi: 10.1038/nm.2610. Nat Med. 2012. PMID: 22366949 Free PMC article.
-
RUNX1 mutation associated with clonal evolution in relapsed pediatric acute myeloid leukemia with t(16;21)(p11;q22).Int J Hematol. 2014 Feb;99(2):169-74. doi: 10.1007/s12185-013-1495-5. Epub 2013 Dec 28. Int J Hematol. 2014. PMID: 24374719
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous